Deep venous disease most often presents as deep vein thrombosis (DVT)—a clot in the deep veins of the leg or pelvis. What begins as an acute event can progress to chronic, resource-intensive disease with lasting patient impact.1, 2
 

~1-2 in 1,000

Adults affected annually3

20–50%

of patients with a DVT develop post-thrombotic syndrome 4,5

~20-25%

adults are affected by venous disease globally 2

~$7-10B annually

venous Thromboembolism healthcare costs in the U.S.7

A Progressive Venous Condition

Deep venous disease is driven by impaired flow, vessel injury, or increased clotting tendency. It may present with pain and swelling—or remain silent.

Left unresolved, it can progress to chronic venous dysfunction, with sustained clinical and economic burden.8, 9

Man on a bed massaging his legs and indicating pain in joints.

Clinical Impact

Recent or sudden blockage of blood flow within the leg, caused by acute thrombus formation within the vein.

Persistent outflow limitation – often iliofemoral and may result in venous hypertension, reduced mobility, and ongoing care requirements.9

A complication occurring in up to half of patients, PTS is a significant source of long-term morbidity. Characterized by chronic pain, edema, skin changes, and ulceration.4,5

An acute, potentially life-threatening consequence of clot migration to the lungs.

Treatment Approaches

Medical Management

First-line care focuses on stabilization and symptom control.

  • Anticoagulation to limit progression and embolization
  • Compression therapy to manage swelling and venous hypertension
  • Mobility, elevation, and supportive care
  • Wound management in advanced disease
Interventional Treatments

Applied in symptomatic patients with significant thrombus burden or outflow obstruction, interventional techniques may include thrombus-removal procedures as well as vessel-reconstruction approaches.

  • Catheter-directed thrombolysis

  • Mechanical or pharmacomechanical thrombectomy

  • Balloon venoplasty

  • Venous stenting

Thrombolysis and thrombectomy are used to remove thrombus.

Balloon venoplasty and venous stenting are used to open and maintain patency.10,11

Restoring Venous Outflow in Obstructive Disease

Residual deep venous obstruction is a key driver of chronic symptoms following DVT. Venous stents provide structural support to maintain vessel patency and restore flow.10,12

Common Use Cases
  • Iliofemoral, iliocaval, or inferior vena cava obstruction
  • Post-thrombotic syndrome with outflow limitation
  • May-Thurner syndrome caused by iliac vein compression
  • Residual stenosis post-thrombus removal
Woman sitting on a sofa with her hands resting on her lower leg.

Underrecognized. Inconsistently Managed.

Chronic deep venous disease remains underdiagnosed and inconsistently treated. Variability in care pathways and limited awareness continue to delay effective intervention.13, 9, 14

Earlier identification and targeted treatment may potentially reduce long-term burden.

A Sustained System Burden

Deep venous disease can have a long-term impact well beyond the initial event. 4,9

  • Chronic wound care and ulcer management
  • Repeat imaging and interventions
  • Ongoing compression therapy
  • Persistent quality-of-life impact

  1. Douketis, JD. Deep Venous Thrombosis (DVT). Merck Manual Professional Version. Updated January 2026. Accessed May 20, 2026. 2026.https://www.merckmanuals.com/professional/cardiovascular-disorders/peripheral-venous-disorders/deep-venous-thrombosis-dvt

  2. Eklof B, Perrin M, Delis KT, Rutherford RB, Gloviczki P. Updated terminology of chronic venous disorders: The VEINTERM transatlantic interdisciplinary consensus document. J Vasc Surg. 2009;49(2):498–501. doi:10.1016/j.jvs.2008.09.014

  3. Scheres LJ, Lijfering WM, Cannegieter SC. Current and future burden of venous thrombosis: not simply predictable. Res Pract Thromb Haemost. 2018;2(2):199–208. doi:10.1002/rth2.12101

  4. Visonà A, Quéré I, Mazzolai L, et al.; European Society of Vascular Medicine (ESVM). Postthrombotic syndrome: a position paper from the European Society of Vascular Medicine. Vasa. 2021;50(5):331–340. doi:10.1024/0301-1526/a000946. [vascular-m...dicine.org]

  5. Rabinovich A, Kahn SR. How I treat the postthrombotic syndrome. Blood. 2018;131(20):2215–2222. doi:10.1182/blood-2018-01-785956.

  6. Ullah I, Ahmad K, Ahmed H, Cortese B. Charting the course and uncharted territories: SCAI 2025 guidelines for chronic venous disease. J Soc Cardiovasc Angiogr Interv. Published online June 30, 2025. doi:10.1016/j.jscai.2025.103729

  7. Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res. 2016;137:3–10. doi:10.1016/j.thromres.2015.11.033

  8. Kahn SR, Comerota AJ, Cushman M, et al.; American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: Evidencebased prevention, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation. 2014;130(18):1636–1661. doi:10.1161/CIR.0000000000000130

  9. Vedantham S, Weinberg I, Desai KR, et al.; Society of Interventional Radiology. Society of Interventional Radiology position statement on the management of chronic iliofemoral venous obstruction with endovascular placement of metallic stents. J Vasc Interv Radiol. 2023;34(10):1643–1657.e6. doi:10.1016/j.jvir.2023.06.013.

  10. Breen K. Role of venous stenting for venous thromboembolism. Hematology Am Soc Hematol Educ Program.2020;2020(1):606–611. doi:10.1182/hematology.2020000147. [ashpublications.org]

  11.  Kakkos SK, Gohel M, Baekgaard N, et al; ESVS Guidelines Committee. European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg. 2021;61(1):9-82. doi:10.1016/j.ejvs.2020.09.023

  12. Barbati ME, Avgerinos ED, Baccellieri D, Doganci S, Lichtenberg M, Jalaie H. Interventional treatment for postthrombotic chronic venous obstruction: Progress and challenges. J Vasc Surg Venous Lymphat Disord. 2024;12(5):101910. doi:10.1016/j.jvsv.2024.101910.

  13. Sudheendra D. The Physician’s Guide to Venous Disease: Diagnosing & Managing Superficial Venous Disease, VTE, & Pelvic Venous Disease. Cleveland Clinic Resident Lecture; June 7, 2021. Presented by 360 Vascular Institute.

  14. Attaran RR, Edwards ML, Arena FJ, et al. 2025 SCAI Clinical Practice Guidelines for the Management of Chronic Venous Disease. J Soc Cardiovasc Angiogr Interv (JSCAI). 2025;4(8):103729. doi:10.1016/j.jscai.2025.103729. [jscai.org]

IFU Consult instructions

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

INDICATIONS FOR USE IN THE U.S.: The GORE® VIABAHN® FORTEGRA Venous Stent is indicated for use in the treatment of symptomatic inferior vena cava obstruction with or without combined iliofemoral obstruction.

CONTRAINDICATIONS: The GORE® VIABAHN® FORTEGRA Venous Stent is contraindicated for use in patients with lesions where expansion of an angioplasty balloon catheter to minimum GORE® VIABAHN® FORTEGRA Venous Stent recommended vessel diameters was not achieved during pre-dilatation, or where lesions cannot be dilated sufficiently to allow passage of the delivery system.

GORE® VIABAHN® FORTEGRA Venous Stent is not authorized for use in Canada.

Products listed may not be approved in all markets.
25PL6011-EN02 MAT-0993-1